Scholarlink

<p>Injectable silk hydrogels, preferred for medical use due to non-surgical administration and slow degradation, were developed at lower concentrations (1.5–3.0 wt.%) by increasing β-sheet content through controlled gelation. Structural transitions from random coil to β-sheets, confirmed by FTIR, enabled slow <i>in vitro</i> degradation. When tested on HepG2 cells, SN-38-Cholesterol–1.5 wt.% silk hydrogel reduced the drug release rate by over half compared to drug nanoparticles alone. With injectability, slow degradation, and controlled drug release, these hydrogels show promise as drug delivery systems for cancer therapy.</p> Graphical abstract <p>Illustration of injectable silk protein hydrogel loaded with SN-38-cholesterol nano-prodrugs applied for localized drug delivery system</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Silk protein-based injectable hydrogel to deliver nano-prodrugs toward localized cancer treatment

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Mengheng Yang,
  • Anh T. N. Dao,
  • Hisayuki Nakatani,
  • Yuki Eguchi,
  • Ryuju Suzuki,
  • Yoshitaka Koseki,
  • Kouki Oka,
  • Hitoshi Kasai

摘要

Injectable silk hydrogels, preferred for medical use due to non-surgical administration and slow degradation, were developed at lower concentrations (1.5–3.0 wt.%) by increasing β-sheet content through controlled gelation. Structural transitions from random coil to β-sheets, confirmed by FTIR, enabled slow in vitro degradation. When tested on HepG2 cells, SN-38-Cholesterol–1.5 wt.% silk hydrogel reduced the drug release rate by over half compared to drug nanoparticles alone. With injectability, slow degradation, and controlled drug release, these hydrogels show promise as drug delivery systems for cancer therapy.

Graphical abstract

Illustration of injectable silk protein hydrogel loaded with SN-38-cholesterol nano-prodrugs applied for localized drug delivery system